14.44
+1.19%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mesoblast
Its shares trade under the ticker MESO. It has been listed since 13 November 2015. In the fiscal year to 30 June 2026, it reported revenue of $120.3m and a net loss of $57.5m. At that date it held total assets of $773.1m and shareholders' equity of $568.4m.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Nov 2015
- Employees
- 81
- Website
- mesoblast.com ↗
- Head office
- LEVEL 38, MELBOURNE, VICTORIA, C3, 3000
- Incorporated in
- C3
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mesoblast Ltd's Remestemcel-L is in Phase III trials for steroid refractory aGVHD in the US.
- Strategic partnership with Tasly Pharmaceutical Group for MPC-150-IM in chronic heart failure.
- MPC-300-IV development for biologic refractory rheumatoid arthritis in Australia.
Weaknesses
- Remestemcel-L Phase III trials for ulcerative colitis face regulatory hurdles in Singapore.
- MPC-25-IC development for acute myocardial infarction lacks US market access.
- MPC-150-IM partnership with Tasly Pharmaceutical Group has limited clinical data.
Opportunities
- Expanding Remestemcel-L trials to Switzerland for chronic low back pain treatment.
- MPC-300-IV could address diabetic nephropathy in the US market.
- JCR Pharmaceuticals Co. Ltd. partnership for pediatric SR-aGVHD in Japan.
Threats
- Phase III trials for Remestemcel-L in Crohn's disease face competition from biologics.
- MPC-150-IM partnership with Tasly Pharmaceutical Group has delayed approvals.
- Regulatory challenges for Remestemcel-L in biologic refractory inflammatory bowel disease.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.